



Prestium Pharma, Inc. Acquires ZONALON[®] (Doxepin Hydrochloride), 5% Cream; Continues to Expand its Product Portfolio

March 18, 2015 04:00 PM Eastern Daylight Time

NEWTOWN, Pa.--(BUSINESS WIRE)--Prestium Pharma, Inc. announced the acquisition of ZONALON[®] (doxepin hydrochloride), 5% Cream, in the U.S. ZONALON[®] is indicated for the short-term (up to eight days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus.

"The acquisition of ZONALON[®] marks another key milestone for Prestium," said John Denman, general manager of Prestium. The acquisition comes as Prestium continues to expand its portfolio with high-quality dermatologic products.

"Pruritus can be a serious condition for patients, affecting their quality of life by impairing the ability to perform daily activities," said Denman. "We are committed to supporting ZONALON[®] in the market so physicians and patients have access to this important medication."

ZONALON[®] is available in 30 g and 45 g sizes. Because doxepin HCl has an anticholinergic effect and because significant plasma levels of doxepin are detectable after topical ZONALON[®] Cream application, the use of ZONALON[®] Cream is contraindicated in patients with untreated narrow angle glaucoma or a tendency to urinary retention. Drowsiness occurs in over 20% of patients treated with ZONALON[®] Cream, especially in patients receiving treatment to greater than 10% of their body surface area. Patients should be warned about the possibility of sedation and cautioned against driving a motor vehicle or operating hazardous machinery while being treated with ZONALON[®] Cream. The sedating effects of alcoholic beverages, antihistamines, and other CNS depressants may be potentiated when ZONALON[®] Cream is used. In controlled clinical trials, the most common adverse events were burning/stinging (23.0%), drowsiness (21.5%), dry mouth including dry lips, dry throat and thirst (9.7%), pruritus including exacerbated pruritus (3.9%) and fatigue/tiredness (3.0%). Learn more about ZONALON[®] Cream and see Full Prescribing Information by visiting zonaloncream.com.

About Prestium Pharma

Prestium Pharma, Inc. is subsidiary of Renaissance Acquisition Holdings LLC and is focused on marketing high quality pharmaceutical brands in the United States. More information on Prestium can be found at <http://www.prestiumpharma.com/>

Contacts

For Prestium Pharma, Inc.

Lea Studer, 308-237-5567

lea@scormarketing.com